Journal Information
Vol. 41. Issue 9.
Pages 484-488 (September 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 9.
Pages 484-488 (September 2005)
Original Articles
Full text access
Use of Blood Products in Patients Treated Surgically for Stage I Non-Small Cell Lung Cancer
Visits
3979
J.C. Peñalver
Corresponding author
jpenalve@ono.com

Correspondence: Dr. J.C. Peñalver. Servicio de Cirugía Torácica. Hospital Universitario La Fe. Avda. de Campanar, 21. 46009 Valencia. España
, J. Padilla, C. Jordá, J. Escrivá, J. Cerón, V. Calvo, A. García, J. Pastor, E. Blasco
Servicio de Cirugía Torácica, Hospital Universitario La Fe, Valencia, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

Retrospective study on the relation between the use of blood products and survival rates in patients treated surgically for stage I non-small cell lung cancer (NSCLC).

Patients and methods

The study included 856 patients who underwent surgical resection from 1969 to 2000 for stage I NSCLC, classified histologically according to the current guidelines of the Spanish Society of Pulmonary and Thoracic Surgery (SEPAR). Patients who died in the postoperative period were excluded from the study. A series of clinicopathological variables were recorded, including the perioperative use or not of blood products. Descriptive, univariate, and multivariate statistical analyses were performed. Follow up concluded in December of 2003.

Results

One hundred twenty-five patients (14.6%) underwent a perioperative transfusion. A significant association was found between the use of blood products and tumor size (P<.001), pneumectomy (P<.001), and cell type (P<.05). The respective 2, 5, and 10-year survival rates were 78%, 63%, and 54% for the nontransfusion group, and 73%, 59%, and 46% for the transfusion group. Both survival curves were compared and no significant differences were found (P = .23). Multivariate regression analysis included tumor size, patient age, and histologic cell type (squamous cell carcinoma or not); no relation between transfusion and survival was found.

Conclusions

In our series, we found no difference in survival rates for patients with stage I NSCLC after perioperative blood transfusion.

Key Words:
Bronchogenic carcinoma
Stage I
Surgery
Transfusion
Objetivo

Estudio retrospectivo sobre la influencia del uso de hemoderivados en la supervivencia del carcinoma broncopulmonar no anaplásico de células pequeñas (CB-NACP) en estadio I sometido a tratamiento quirúrgico.

Pacientesy métodos

Se incluyó en el estudio a 856 pacientes (1969-2000) diagnosticados de CBNACP, que se resecaron y clasificaron como estadio I patológico según la actual normativa SEPAR, y se excluyó la mortalidad postoperatoria. Se recogieron una serie de variables clinicopatológicas, incluida la utilización o no de hemoderivados en el perioperatorio, y se aplicaron análisis estadísticos descriptivos, univariante y multivariante. El seguimiento finalizó en diciembre de 2003.

Resultados

En el perioperatorio se transfundió a 125 pacientes (14,6%). La utilización de hemoderivados se relacionó significativamente con el tamaño tumoral (p < 0,001), la realización de una neumonectomía (p < 0,001) y el tipo histológico (p < 0,05). La supervivencia fue del 78, el 63 y el 54% a los 2, 5 y 10 años, respectivamente, para el grupo de pacientes no transfundidos, y del 73, el 59 y el 46% para el grupo de transfundidos. La comparación de ambas curvas de supervivencia no mostró diferencias significativas (p = 0,23). En el análisis multivariante entraron en regresión el tamaño tumoral, la edad y la variedad histológica epidermoide/no epidermoide. En este análisis no se demostró ninguna relación de la transfusión con la supervivencia.

Conclusiones

No se ha encontrado, en nuestra serie, ninguna variación en la supervivencia del CBNACP en estadio I tras el uso de hemoderivados en el perioperatorio inmediato.

Palabras clave:
Carcinoma broncogénico
Estadio I
Cirugía
Transfusión
Full text is only aviable in PDF
REFERENCES
[1]
MD Smith, JD Williams, GA Coles, JR Salaman.
The effect of blood transfusion on T-suppressor cells in renal dialysis patients.
Transplant Proc, 13 (1981), pp. 181-183
[2]
G Opelz, B Graver, PI Terasaki.
Induction of high kidney graft survival rate by multiple transfusion.
Lancet, 1 (1981), pp. 1223-1225
[3]
PI Tartter, L Burrows, P Kirschner.
Perioperative blood transfusion adversely affects prognosis after resection of stage I (subset N0) non-oat cell lung cancer.
J Thorac Cardiovasc Surg, 88 (1984), pp. 659-662
[4]
NH Hyman, RS Foster Jr, JE DeMeules, MC Costanza.
Blood transfusions and survival after lung cancer resection.
Am J Surg, 149 (1985), pp. 502-507
[5]
DW Moores, S Piantadosi, MF McKneally.
Effect of perioperative blood transfusion on outcome in patients with surgically resected lung cancer.
Ann Thorac Surg, 47 (1989), pp. 346-351
[6]
AG Little, HS Wu, MK Ferguson, CH Ho, VD Bowers, A Segalin, et al.
Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer.
Am J Surg, 160 (1990), pp. 630-632
[7]
S Piantadosi, DW Moores, MF McKneally.
The adverse effect of perioperative blood transfusion in lung cancer.
Chest, 106 (1994), pp. 382-384
[8]
M Nosotti, P Rebulla, D Riccardi, A Baisi, N Bellaviti, L Rosso, et al.
Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer.
Chest, 124 (2003), pp. 102-107
[9]
U Pastorino, M Valente, I Cataldo, C Lequaglie, G Ravasi.
Perioperative blood transfusion and prognosis of resected stage Ia lung cancer.
Eur J Cancer Clin Oncol, 22 (1986), pp. 1375-1378
[10]
SM Keller, S Groshen, N Martini, LR Kaiser.
Blood transfusion and lung cancer recurrence.
Cancer, 62 (1988), pp. 606-610
[11]
CM Pena, TW Rice, M Ahmad, SV Medendorp.
Significance of perioperative blood transfusions in patients undergoing resection of stage I and II non-small-cell lung cancers.
Chest, 102 (1992), pp. 84-88
[12]
K Novak, J Vodicka, M Pesek.
Survival after surgery for bronchogenic carcinoma in relation to blood transfusion.
Rozhl Chir, 73 (1994), pp. 110-113
[13]
J Casanova Viudez, M Marinan Gorospe, V Sobradillo Pena, FI Zuazua Verde, JI Pijoan Zubizarreta.
Influencia de la transfusión perioperatoria en la supervivencia de los carcinomas de pulmón resecados.
Arch Bronconeumol, 35 (1999), pp. 417-421
[14]
Grupo de Trabajo de la SEPAR.
Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico.
Arch Bronconeumol, 34 (1998), pp. 437-452
[15]
WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, in collaboration with Sobin LH and pathologists from 14 countries.
World Health Organization International histological classification of tumours. Histological typing of lung and pleural tumours, 3rd ed., Springer-Verlag, (1999),
[16]
EL Kaplan, P Meier.
Non parametric estimation from incomplete observations.
J Am Stat Assoc, 53 (1958), pp. 457-481
[17]
DR Cox.
Regression models and life tables.
J R Stat Soc, 34 (1972), pp. 187-220
[18]
PA Kirschner.
Does transfusion modify the outcome of cancer resections?.
Ann Thorac Surg, 47 (1989), pp. 336-337
[19]
EC Vamvakas.
Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation.
Transfusion, 35 (1995), pp. 760-768
[20]
FA McAlister, HD Clark, PS Wells, A Laupacis.
Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies.
[21]
P Rainio, R Bloigu, J Satta, R Pokela, P Paakko.
Ten-year survival after resection for lung carcinoma. Effect of blood transfusion and tumour stage on outcome.
Scand J Thorac Cardiovasc Surg, 30 (1996), pp. 87-91
[22]
W Rzyman, R Dziadziuszko, J Skokowski, R Wilimski, A Raiter, A Szymanowska, et al.
The influence of blood transfusion on survival in operated non-small cell lung cancer patients.
J Thorac Cardiovasc Surg, 126 (2003), pp. 755-760
[23]
D Dougenis, V Patrinou, KS Filos, E Theodori, K Vagianos, A Maniati.
Blood use in lung resection for carcinoma: perioperative elective anaemia does not compromise the early outcome.
Eur J Cardiothorac Surg, 20 (2001), pp. 372-377
[24]
HS Wu.
Influence of blood transfusion on postoperative prognosis of stage I (N0) lung cancer.
Zhonghua Zhong Liu Za Zhi, 11 (1989), pp. 297-299
[25]
JL Gwin, SM Keller.
Blood transfusion practices after resection of intrathoracic neoplasms.
J Surg' Oncol, 54 (1993), pp. 34-37
[26]
T Zimmermann, J Dobroschke, C Becker, C Kelm, WM Padberg.
Effect of perioperative donor blood transfusion on prognosis of bronchial cancer.
Langenbecks Arch Chir, 378 (1993), pp. 145-149
[27]
K Hallfeldt, JM Megevand, M Sohn, O Thetter.
Differed autologous blood transfusion and its effects during pulmonary lobectomy.
J Chir (Paris), 131 (1994), pp. 562-567
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?